HQL vs. GAB, STEW, CET, GAM, QQQX, MUC, MFIC, HQH, MQY, and SLRC
Should you be buying Abrdn Life Sciences Investors stock or one of its competitors? The main competitors of Abrdn Life Sciences Investors include The Gabelli Equity Trust (GAB), SRH Total Return Fund (STEW), Central Securities (CET), General American Investors (GAM), Nuveen Nasdaq 100 Dynamic Overwrite Fund (QQQX), BlackRock MuniHoldings California Quality Fund (MUC), MidCap Financial Investment (MFIC), Abrdn Healthcare Investors (HQH), BlackRock MuniYield Quality Fund (MQY), and SLR Investment (SLRC). These companies are all part of the "investment offices, not elsewhere classified" industry.
The Gabelli Equity Trust (NYSE:GAB) and Abrdn Life Sciences Investors (NYSE:HQL) are both small-cap finance companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment, community ranking and dividends.
7.2% of The Gabelli Equity Trust shares are owned by institutional investors. Comparatively, 32.2% of Abrdn Life Sciences Investors shares are owned by institutional investors. 0.9% of The Gabelli Equity Trust shares are owned by company insiders. Comparatively, 10.1% of Abrdn Life Sciences Investors shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
The Gabelli Equity Trust pays an annual dividend of $0.60 per share and has a dividend yield of 11.1%. Abrdn Life Sciences Investors pays an annual dividend of $1.49 per share and has a dividend yield of 9.7%.
In the previous week, Abrdn Life Sciences Investors had 2 more articles in the media than The Gabelli Equity Trust. MarketBeat recorded 3 mentions for Abrdn Life Sciences Investors and 1 mentions for The Gabelli Equity Trust. The Gabelli Equity Trust's average media sentiment score of 0.93 beat Abrdn Life Sciences Investors' score of -1.00 indicating that Abrdn Life Sciences Investors is being referred to more favorably in the news media.
The Gabelli Equity Trust has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Abrdn Life Sciences Investors has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.
The Gabelli Equity Trust received 62 more outperform votes than Abrdn Life Sciences Investors when rated by MarketBeat users. However, 68.35% of users gave Abrdn Life Sciences Investors an outperform vote while only 63.82% of users gave The Gabelli Equity Trust an outperform vote.
Summary
Abrdn Life Sciences Investors beats The Gabelli Equity Trust on 5 of the 8 factors compared between the two stocks.
Get Abrdn Life Sciences Investors News Delivered to You Automatically
Sign up to receive the latest news and ratings for HQL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HQL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Abrdn Life Sciences Investors Competitors List
Related Companies and Tools
Free HQL Stock Alerts